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ABSTRACT
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance 
to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as 
osimertinib and nazartinib, are effective for patients with the EGFR T790M mutation. 
However, there are no direct comparison data to guide the selection of a third-
generation EGFR-TKI for patients with different EGFR mutations. We previously 
established an in vitro model to estimate the therapeutic windows of EGFR-TKIs by 
comparing their relative efficacies against cells expressing mutant or wild type EGFRs. 
The present study used this approach to characterize the efficacy of third-generation 
EGFR-TKIs and compare them with that of other EGFR-TKIs. Treatment efficacy was 
examined using human lung cancer-derived cell lines and Ba/F3 cells, which were 
transduced with clinically relevant mutant EGFRs. Interestingly, mutation-related 
differences in EGFR-TKI sensitivity were observed. For classic EGFR mutations (exon 
19 deletion and L858R, with or without T790M), osimertinib showed lower IC50 values 
and wider therapeutic windows than nazartinib. For less common EGFR mutations 
(G719S or L861Q), afatinib showed the lowest IC50 values. For G719S+T790M or 
L861Q+T790M, the IC50 values of osimertinib and nazartinib were around 100 nM, 
which was 10- to 100-fold higher than those for classic+T790M mutations. On the 
contrary, osimertinib and nazartinib showed similar efficacies in cells expressing EGFR 
exon 20 insertions. The findings highlight the diverse mutation-related sensitivity 
pattern of EGFR-TKIs. These data may help in the selection of EGFR-TKIs for non-small 
cell lung cancer patients harboring EGFR mutations.
INTRODUCTION
Lung cancer is the leading cause of cancer-related 
death worldwide [1]. A significant proportion of non-
small cell lung cancers (NSCLCs) carry epidermal 
growth factor receptor (EGFR) gene mutations [2–6], 
which have been identified in approximately 10–30% of 
NSCLCs [7, 8]. Somatic mutation of the EGFR tyrosine 
kinase domain promotes the active conformation of this 
receptor, hence inducing its constitutive activation [9–
11]. Activated EGFR transduces downstream signals, 
including the extracellular signal-regulated kinase (ERK)/
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mitogen-activated protein kinase (MAPK) pathway, and 
phosphatidylinositol-3-kinase/protein kinase B (AKT) 
[12–14]. The most common or “classic” mutations are in-
frame deletions around the LREA motif in exon 19, which 
account for approximately 45% of EGFR mutations, 
and the exon 21 L858R point mutation, accounting for 
approximately 40% of EGFR mutations. Other less 
common EGFR mutations include G719X (3% of EGFR 
mutations), L861Q (2% of EGFR mutations) [12], and 
exon 20 insertion mutations (4–10% of EGFR mutations) 
[15–17].
EGFR tyrosine kinase inhibitors (EGFR-TKIs) 
have been developed to inhibit EGFR-mediated signaling. 
These molecules bind reversibly or irreversibly to the ATP 
binding pocket of EGFR, thus inhibiting activation. The 
exon 19 deletions, the L858R, the G719X, and the L861Q 
mutations result in sensitivity to the first-generation 
EGFR-TKIs, gefitinib and erlotinib. The response rates 
to gefitinib or erlotinib among NSCLC patients harboring 
the classic EGFR mutations are around 60–80% [7, 18]. 
Acquired resistance can occur after treatment with first- 
or second-generation EGFR-TKIs and the EGFR T790M 
mutation accounts for about 60% of this resistance [19, 
20]. EGFR T790M is thought to induce resistance to 
these EGFR-TKIs by decreasing the affinity of EGFR-
TKIs and increasing the affinity of ATP to tyrosine kinase 
domain ATP binding pocket of EGFR [20, 21]. Third-
generation EGFR-TKIs irreversibly bind to the EGFR 
ATP binding pocket via a covalent interaction with the 
C797 residue, thereby blocking the increased affinity for 
ATP conferred by the EGFR T790M mutation. Some of 
third-generation EGFR-TKIs such as osimertinib [22]
and nazartinib, which was formerly called EGF816, have 
demonstrated clinically significant efficacy and safety 
in NSCLC patients harboring EGFR T790M mutations, 
although the development of other third-generation 
candidates (rociletinib, olmutinib and naquotinib) has been 
halted [23, 24]. Osimertinib treatment produced a high 
objective response rate of approximately 60% for tumors 
with T790M mutations that showed resistance to first-
generation EGFR-TKIs [22]. Nazartinib is undergoing 
clinical evaluation [25].
Unlike classic EGFR mutations, there is a paucity of 
data regarding the EGFR-TKI sensitivity of patients with 
lung cancers expressing less common EGFR mutations. 
For tumors expressing some of these mutations such as 
G719X, L861Q, and S768I, afatinib was effective [26]. 
However, the efficacy of third-generation EGFR-TKIs in 
patients with these mutations, in the presence or absence 
of the T790M mutation, is unclear.
On the other hand, most EGFR exon 20 insertion 
mutations confer resistance to first- and second-generation 
EGFR-TKIs [15, 27, 28]. One exception is EGFR 
A763_Y764insFQEA, which we previously reported 
as a first-generation EGFR-TKI-sensitizing mutation 
[29]. Our previous study reported the potential efficacy 
of osimertinib against tumors with exon 20 insertions 
associated with first- and second-generation EGFR-TKI 
resistance [30]. We created an in vitro model to determine 
the therapeutic windows for EGFR-TKIs, where the ratios 
of the 50% inhibitory concentrations (IC50) in Ba/F3 cells 
transduced with either mutated or wild type EGFRs were 
calculated [30]. We identified a therapeutic window of 
osimertinib for several EGFR exon 20 insertion mutations. 
The efficacy of nazartinib against cells expressing EGFR 
exon 20 insertion mutations has also been reported 
previously [31]. These authors revealed that nazartinib 
potently inhibited major subtypes of exon 20 insertion 
mutations, with EC50 values of 7, 11, and 190 nmol/L 
against D770_V771dupSVD, V769_D770insASV, and 
H773_V774insNPH, respectively. Furthermore, they 
showed an antitumor effect of nazartinib in a mouse 
patient-derived xenograft model expressing H773_
V774insNPH. Therefore, osimertinib and nazartinib are 
expected to be potentially effective for tumors with exon 
20 insertion mutations.
There are no direct comparison data relating to the 
efficacies of EGFR-TKIs for tumors expressing different 
EGFR mutations, including the less common mutations. 
The present study aimed to characterize the efficacy of 
third-generation EGFR-TKIs and to compare them with 
that of other EGFR-TKIs using in vitro modeling. This 
analysis of the efficacy of EGFR-TKIs provides preclinical 
information to inform the proper selection of EGFR-TKIs 
for the treatment of patients with cancers harboring EGFR 
mutations.
RESULTS
Therapeutic windows for osimertinib and 
nazartinib in Ba/F3 cells expressing classic 
EGFR mutations, in the presence or absence of 
T790M
We generated stable EGFR-expressing Ba/F3 
cell lines in order to directly compare the sensitivities 
of multiple EGFR mutations to EGFR-TKIs using 
MTS assays (Figure 1A). The viabilities of Ba/F3 cells 
harboring exon 19del or L858R were dramatically 
reduced by afatinib. Erlotinib also effectively inhibited 
the proliferation of these cells, although it was less potent 
than afatinib. The potency of nazartinib was comparable 
to that of erlotinib, while osimertinib was more potent than 
either erlotinib or nazartinib. Although low concentrations 
of erlotinib did not inhibit the proliferation of Ba/F3 cells 
harboring EGFR T790M mutations (EGFR exon 19del + 
T790M or L858R + T790M), afatinib, osimertinib, and 
nazartinib effectively reduced the viability of these cells.
In the clinic, skin rashes and diarrhea are common 
or life-threatening side effects of EGFR-TKIs. These side 
effects are most likely caused by the inhibition of wild 
type EGFR expressed in epithelial cells within the lungs, 
Oncotarget105481www.impactjournals.com/oncotarget
gastrointestinal tract, and skin. Hence, the clinical utility 
of EGFR-TKIs is hampered by their lack of selectivity 
for mutated versus wild type EGFR; this results in a 
narrow therapeutic window, with a high level of toxicity 
at the clinical doses required to effectively inhibit mutated 
EGFR. We therefore evaluated the effects of EGFR-TKIs 
on wild type EGFR using the MTS assay. Wild type 
EGFR-expressing Ba/F3 cells were efficiently inhibited 
by afatinib, while low concentrations of nazartinib did not 
inhibit their viability. The IC50 value for afatinib was 30 
nM, as compared to 1031 nM for nazartinib, indicating 
that afatinib had more potent effects on wild type EGFR. 
The IC50 values for each EGFR-TKI examined in this 
study are summarized in Table 1.
We used in vitro modeling to calculate the selectivity 
index (SI): the ratio of IC50 values in Ba/F3 cells 
transduced with mutant or wild type EGFRs (Figure 1B). 
In this model, a low SI value indicates a highly mutant 
EGFR-selective EGFR-TKI. For Ba/F3 cells harboring 
exon 19del or L858R, osimertinib showed the lowest 
Figure 1: The sensitivity of Ba/F3 cells expressing wild type (WT) or mutant EGFR to EGFR-TKIs. (A) MTS assays were 
conducted in Ba/F3 cells expressing the indicated EGFR genotypes. Data points represent the mean ± standard deviation. (B) Selectivity 
index (SI) values were calculated for cells expressing the indicated EGFR mutations versus wild type.*; SI index >1.
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SI values of the EGFR-TKIs included in this study; this 
indicated a wide therapeutic window for osimertinib in 
patients with these mutations. Nazartinib showed slightly 
higher SI values than osimertinib in cells expressing 
classic EGFR mutations. For Ba/F3 cells harboring EGFR 
T790M, osimertinib and nazartinib showed striking 
mutation specificity. Their SI values of ≤ -2 indicated 
IC50 values for cells expressing the T790M mutation that 
were > 100-fold lower than those for cells expressing wild 
type EGFR. On the other hand, erlotinib and afatinib did 
not demonstrate mutation specificity for EGFR T790M 
mutations. These SI values were > 0, indicating IC50 
values for cells expressing EGFR T790M were higher than 
those for cells expressing wild type EGFR.
Effect of EGFR-TKIs on EGFR downstream 
signals and apoptosis in cells Ba/F3 expressing 
classic EGFR mutations in the presence or 
absence of the T790M mutation
To examine EGFR signaling pathways, we 
performed immunoblotting (Supplementary Figure 1A). 
In Ba/F3 cells harboring exon 19del or L858R, afatinib 
dramatically inhibited the phosphorylation of EGFR, 
AKT, and ERK. Erlotinib, osimertinib, and nazartinib 
inhibited the phosphorylation of EGFR, AKT, and ERK 
to a similar extent. In Ba/F3 cells harboring the EGFR 
T790M mutation (exon 19del + T790M or L858R + 
T790M), erlotinib did not inhibit the phosphorylation of 
EGFR, AKT, and ERK. However, afatinib, osimertinib, 
and nazartinib did effectively inhibit the phosphorylation 
of these molecules. These data indicated that the 
sensitivity of Ba/F3 cells to EGFR-TKIs was reflected by 
the inhibition of the EGFR and its downstream signaling 
pathways.
Next, to biologically confirm the therapeutic 
windows for third-generation EGFR-TKIs in cells 
expressing the T790M mutation, we analyzed apoptosis 
in Ba/F3 cells expressing wild type EGFR or EGFR exon 
19del + T790M. We stained these cells with annexin 
V-APC and propidium iodide after 48-h exposures to 
the indicated EGFR-TKIs (0.1 μM). The proportions of 
annexin V-positive and/or propidium iodide-positive 
cells were examined by flow cytometry (Supplementary 
Figure 1B). As expected, afatinib induced apoptosis in Ba/
F3 cells harboring either wild type EGFR or EGFR exon 
19del + T790M, indicating a narrow therapeutic window 
for afatinib in the presence of EGFR exon 19del + T790M. 
The proportion of annexin V-positive wild type EGFR-
expressing cells was 91.0%, as compared with 32.8% of 
EGFR exon 19del + T790M-expressing cells. In contrast, 
osimertinib and nazartinib produced only minor effects 
on apoptosis in Ba/F3 cells harboring wild type EGFR, 
and were more effective in cells harboring EGFR exon 
19del + T790M. The proportions of annexin V-positive 
wild type EGFR-expressing cells were 27.9% and 25.5%, 
respectively, in the presence of osimertinib and nazartinib, 
while the equivalent values for cells expressing EGFR 
exon 19del + T790M were 72.5% and 62.8%, respectively. 
These data indicated a wide therapeutic window for 
osimertinib and nazartinib in the treatment of tumors 
expressing the EGFR T790M mutation.
Table 1: IC50 values (nM) of Ba/F3 cells expressing EGFR mutations
Mutations erlotinib afatinib osimertinib nazartinib
exon 19del 73 0.6 7.9 66
L858R 30 0.6 6.2 35
G719S 101 1.5 158 91.2
L861Q 410 3.6 35.8 116
A763_Y764insFQEA 152 <0.1 24 78
Y764_V765insHH 2948 140 143 387
A767_V769dupASV 3073 77 134 257
D770_N771insNPG 2342 36 28 84
exon19del+T790M 3429 146 3.1 52
L858R+T790M >10000 179 0.9 5.1
G719S+T790M >10000 34 97 77
L861Q+T790M >10000 163 73 101
exon19del+T790M+C797S 5153 390 655 2146
L858R+T790M+C797S 8360 826 1024 3834
WT 638 30 516 1031
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Investigation of the sensitivity/resistance profiles 
of EGFR-TKIs in lung cancer cell lines
To explore the relevance of the sensitivity/
resistance profiles derived from stably transduced Ba/
F3 cells, we also performed MTS assays in human lung 
cancer-derived cell lines in the presence and absence 
of EGFR-TKIs (Figure 2A). The lung cancer cell lines 
included in this study were PC-9 (EGFR exon 19del), PC-
9ER (EGFR exon 19del + T790M), and H1975 (EGFR 
L858R + T790M). For PC-9 cells, afatinib produced the 
most dramatic inhibitory effect, with an IC50 value of 
1.3 nM. Although less potent than afatinib, erlotinib also 
effectively inhibited the proliferation of PC-9 cells, with 
an IC50 value of 28 nM. The potencies of osimertinib and 
nazartinib were comparable to that of erlotinib in this cell 
line, with IC50 values of 23 nM and 36 nM, respectively. 
Low concentrations of erlotinib did not inhibit the 
proliferation of cell lines harboring the EGFR T790M 
mutation (PC-9ER and H1975). However, afatinib and the 
third-generation EGFR-TKIs, osimertinib and nazartinib, 
effectively inhibited the proliferation of these lung cancer 
cells. The calculated IC50 values of afatinib, osimertinib, 
and nazartinib for PC-9ER cells were 677 nM, 166 nM, 
and 276 nM, respectively. The calculated IC50 values 
of afatinib, osimertinib, and nazartinib for H1975 cells 
were 80 nM, 4.6 nM, and 52 nM, respectively. These 
IC50 values are summarized in Supplementary Table 1. 
These data indicated that the sensitivity/resistance profile 
data produced in stably transfected Ba/F3 cells were 
comparable to those generated using human lung cancer 
cell lines.
Furthermore, immunoblotting was performed to 
determine whether the sensitivity of lung cancer cells to 
EGFR-TKIs was mediated through inhibition of EGFR 
signaling (Figure 2B). Consistent with the results of the 
MTS assay, afatinib caused the most potent inhibition of 
the phosphorylation of EGFR and its downstream proteins, 
AKT and ERK, in PC-9 cells. Although they were less 
potent than afatinib, erlotinib, osimertinib, and nazartinib 
also effectively inhibited the phosphorylation of EGFR, 
AKT, and ERK in PC-9 cells. Our study of lung cancer 
cells harboring the EGFR T790M mutation showed that all 
of the tested EGFR-TKIs, except for erlotinib, effectively 
inhibited the phosphorylation of the EGFR, AKT, and 
ERK. In summary, these data indicated that the sensitivity/
resistance profiles observed in Ba/F3 cells were also 
present in human lung cancer cells.
Therapeutic windows of nazartinib and 
osimertinib in Ba/F3 cells expressing EGFR exon 
20 insertion mutations
We investigated the effects of EGFR-TKIs on the 
viability of Ba/F3 cells transduced with four representative 
EGFR exon 20 insertion mutations (A763_Y764insFQEA, 
Y764_V765insHH, A767_V769dupASV, and D770_
N771insNPG) using MTS assays (Figure 3A). All of 
the tested EGFR-TKIs inhibited the growth of Ba/F3 
cells harboring EGFR A763_Y764insFQEA. A similar 
response pattern was observed in a human lung cancer-
derived cell line (BID007) harboring EGFR A763_
Y764insFQEA (Supplementary Figure 2). Afatinib, 
osimertinib, and nazartinib showed comparable efficacies 
against cells expressing other first- and second-generation 
EGFR-TKI-resistant EGFR exon 20 insertion mutations, 
Y764_V765insHH, A767_V769dupASV, and D770_
N771insNPG. The calculated IC50 values are summarized 
in Table 1. We applied the aforementioned in vitro model 
to estimate the therapeutic windows for EGFR-TKIs 
in cells expressing EGFR exon 20 insertion mutations 
(Figure 3B). In Ba/F3 cells harboring EGFR A763_
Y764insFQEA, all EGFR-TKIs showed comparable SI 
values of around -1. In contrast, erlotinib and afatinib had 
SI values > 0 in cells expressing EGFR exon 20 insertion 
mutations associated with resistance to first- and second-
generation EGFR-TKIs. In these cell lines, osimertinib 
and nazartinib had SI values of around -1, indicating IC50 
values of about 10-fold lower than those observed in cells 
expressing wild type EGFR. These data indicated that 
both osimertinib and nazartinib could have therapeutic 
windows and act effectively against cells expressing these 
exon 20 insertion mutations.
Effects of EGFR-TKIs on EGFR downstream 
signals and apoptosis in cells expressing EGFR 
exon 20 insertion mutations
We performed immunoblotting to investigate 
whether the sensitivity of Ba/F3 cells harboring EGFR 
exon 20 insertion mutations was associated with inhibition 
of the EGFR signaling pathway (Supplementary Figure 
3A). As expected, afatinib dramatically inhibited the 
phosphorylation of EGFR, AKT, and ERK in cells 
expressing EGFR A763_Y764insFQEA. Osimertinib and 
nazartinib produced similar inhibitions of EGFR, AKT, 
and ERK phosphorylation. These inhibition patterns 
were also observed in BID007 cells (Supplementary 
Figure 3B). In cells expressing other EGFR exon 20 
insertion mutations associated with resistance to first- 
and second-generation EGFR-TKIs (Y764_V765insHH, 
A767_V769dupASV, and D770_N771insNPG), afatinib, 
osimertinib, and nazartinib produced similar inhibition 
patterns.
We performed assays to determine the level of 
apoptosis in Ba/F3 cells harboring Y764_V765insHH 
and A767_V769dupASV, following exposure to 0.1 
μM afatinib, osimertinib, or nazartinib for 48 h. The 
proportions of annexin V- and/or propidium iodide-positive 
cells were determined by flow cytometry (Supplementary 
Figure 4). In cells expressing Y764_V765insHH, the 
proportions of annexin V-positive cells following exposure 
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to afatinib, osimertinib, or nazartinib were 64.2%, 72.9%, 
or 51.3%, respectively. The corresponding proportions in 
cells expressing A767_V769dupASV were 88.5%, 73.3%, 
or 48.9%, respectively. These data indicated that afatinib, 
osimertinib, and nazartinib induced apoptosis in cells 
expressing different EGFR exon 20 insertion mutations.
Therapeutic windows of osimertinib and 
nazartinib in Ba/F3 cells expressing EGFR 
G719S, L861Q, and/or T790M
We used MTS assays to investigate the effects of 
EGFR-TKIs on the viability of Ba/F3 cells transduced 
with the less common EGFR mutations, G719S and 
L861Q, in the presence or absence of T790M (Figure 
4A). The resultant IC50 values are summarized in Table 
1. The viability of Ba/F3 cells harboring G719S and 
L861Q mutations was dramatically reduced by afatinib. 
For these mutations, the SI values of all EGFR-TKIs 
were < 0, and afatinib showed the lowest SI values in 
cells expressing G719S (Figure 4B). In the presence of 
T790M, the sensitivities to erlotinib and afatinib reduced. 
For G719S+T790M or L861Q+T790M, the IC50 values 
of osimertinib and nazartinib were around 100 nM, 10- to 
100-fold higher than those observed in cells expressing 
classic+T790M mutations (Table 1). Moreover, the SI 
values of osimertinib and nazartinib for these mutations 
were around -1 (Figure 4B), higher than those observed in 
cells expressing classic mutations. These data indicate the 
possibility that third-generation EGFR-TKIs would have 
lower efficacies in tumors expressing the less common 
EGFR mutations, as compared with those expressing the 
classic EGFR mutations, regardless of T790M mutation.
Effects of EGFR-TKIs on EGFR downstream 
signals and apoptosis in cells expressing EGFR 
G719S, L861Q, and/or T790M
We performed immunoblotting to investigate the 
effect of EGFR-TKIs on the EGFR signaling pathway 
(Supplementary Figure 5A). Afatinib dramatically 
inhibited the phosphorylation of EGFR, AKT, and ERK, 
particularly in cells expressing EGFR G719S+T790M. 
Osimertinib and nazartinib produced similar inhibitions 
of EGFR, AKT, and ERK phosphorylation in cells 
expressing G719S+T790M and L861Q+T790M. The level 
of apoptosis in Ba/F3 cells harboring these mutations were 
consistent with the IC50 values for these EGFR-TKIs 
(Supplementary Figure 5B).
The efficacy of osimertinib in NSCLC patients 
harboring G719X in the presence or absence of 
T790M
To seek the clinical relevance of the obtained data 
about the G719X mutation, we reviewed clinical data. In 
the AURA trial, a phase I/II clinical trial (NCT01802632), 
a total of seven patients with the G719X mutation 
received at least one dose of osimertinib. EGFR T790M 
was detected in three of these patients. Of the 7 patients, 
Figure 2: The sensitivities of lung cancer cell lines to EGFR-TKIs. (A) MTS assays of PC-9, PC9-ER, and H1975 cells exposed 
to the indicated EGFR-TKIs. Data points represent the mean ± standard deviation. (B) PC-9, PC9-ER, and H1975 cells were treated with 
the indicated concentrations of EGFR-TKIs for 4 h prior to immunoblotting for the phosphorylated (p) and non-phosphorylated forms of 
EGFR, AKT, and ERK. Actin was used as a loading control.
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Figure 3: The EGFR-TKI sensitivity of Ba/F3 cells harboring the indicated EGFR genotypes. (A) MTS assays were 
conducted in Ba/F3 cells harboring the indicated EGFR exon 20 insertion mutations. Data points represent the mean ± standard deviation. 
(B) The selectivity index (SI) values are shown for the indicated EGFR-TKIs in Ba/F3 cells expressing the indicated EGFR exon 20 
insertion mutations.
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Figure 4: The EGFR-TKI sensitivity of Ba/F3 cells harboring the indicated EGFR genotypes. (A) MTS assays were 
conducted in Ba/F3 cells harboring the indicated EGFR uncommon mutations, G719S and L861Q in the presence or absence of T790M. 
Data points represent the mean ± standard deviation. (B) The selectivity index (SI) values are shown for the indicated EGFR-TKIs in Ba/
F3 cells expressing the indicated EGFR uncommon mutations. *; SI index >1.
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1 (14%) had a confirmed partial response, 3 (43%) had 
stable disease, and 3 (43%) had progressive disease. 
In addition, we identified an interesting case in our 
institution. A 63-year-old woman was diagnosed with 
stage IV adenocarcinoma of the lung via biopsy using 
bronchoscopy. This tumor expressed the EGFR G719S 
mutation. The timeline of her anticancer treatment is 
shown in Figure 5A. Treatment with erlotinib maintained 
stable pulmonary lesions, but did not control her brain 
metastases; she therefore underwent γ-knife and brain 
surgery. After 10 months, the left upper lobe tumor 
had expanded and she received afatinib as a second-
line therapy. After 11 months, the left upper lobe lesion 
enlargement led to a second computed tomography-
guided biopsy. Molecular analysis found EGFR G719S 
and T790M mutations. The patient was then treated with 
osimertinib (80 mg/day). However, after 3 months, she 
met the definition of progressive disease (+ 127%) because 
the left upper lobe tumor had expanded (Figure 5B) and 
left adrenal gland involvement was detected (not shown). 
These findings may reflect the limited efficacy of third-
generation EGFR-TKIs for tumors expressing G719X, in 
the presence or absence of T790M.
EGFR-TKI resistance in cells expressing the 
EGFR C797S mutation
To date, several mechanisms underlying acquired 
resistance to third-generation EGFR-TKIs have been 
reported in preclinical models and clinical specimens; 
these include the tertiary EGFR C797S mutation [32–
35] that prevents the covalent binding of EGFR-TKIs, 
Figure 5: (A) Clinical course after diagnosis of NSCLC. (B) Clinical response to osimertinib in a patient with NSCLC harboring EGFR 
G719S+T790M. Chest computed tomography images of the patient were captured before and after osimertinib treatment.
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EGFR L718Q mutation [36, 37], MET amplification 
[31, 32], HER2 amplification [32], mutated EGFR allele 
amplification [38], or wild type EGFR allele amplification 
[39]. Cys797 is the amino acid that is covalently modified 
by third-generation EGFR-TKIs and its substitution by 
Ser797 abolishes this interaction. We investigated the 
effects of EGFR-TKIs on the viability of Ba/F3 cells 
harboring delL747_P753insS + T790M + C797S (exon 
19del + T790M + C797S) or L858R + T790M + C797S 
using MTS assays (Supplementary Figure 6A). None of 
the tested EGFR-TKIs inhibited the proliferation of these 
cells at low concentrations. The IC50 values of EGFR-
TKIs for EGFR C797S-positive cell lines are summarized 
in Table 1. Furthermore, the SI values of the tested EGFR-
TKIs were > 0 (Supplementary Figure 6B). In summary, 
these data confirmed that Ba/F3 cells expressing the EGFR 
C797S mutation were resistant to these EGFR-TKIs.
DISCUSSION
The present study compared the effects of erlotinib, 
afatinib, osimertinib, and nazartinib on cells expressing a 
range of EGFR mutations; these included classic mutations 
(exon 19 deletions and L858R), the T790M mutation, less 
common mutations (G719S, L861Q and exon 20 insertion 
mutations), and the C797S mutation. The therapeutic 
window for these EGFR-TKIs is an important determinant 
of their potential toxicity in humans. To quantify this, we 
used our previously reported in vitro model to determine 
the ratio of their IC50 values in Ba/F3 cells transduced 
with mutant or wild type EGFRs [30]. In general, the 
SI values obtained in this study were tightly matched to 
previously published data [30], indicating the robustness 
of this model.
In addition, the findings of our studies in stably 
transduced Ba/F3 cell lines and in human lung cancer-
derived cell lines were consistent. All the tested EGFR-
TKIs demonstrated wide therapeutic windows in cells 
expressing the classic EGFR mutations, exon 19 deletions 
and L858R. Interestingly, osimertinib had a wider 
therapeutic window than nazartinib. On the contrary, in 
cells expressing the EGFR T790M mutation, osimertinib 
and nazartinib showed markedly wider therapeutic 
windows than either erlotinib or afatinib. These data 
indicate that osimertinib and nazartinib could provide 
effective and safe EGFR-TKIs for patients with EGFR 
T790M-positive tumors. This is consistent with human 
clinical trials, in which osimertinib and nazartinib have 
shown promising safety and efficacy [22].
Unlike classic EGFR mutations, there is a paucity of 
data regarding the EGFR-TKI sensitivity of patients with 
lung cancers expressing less common EGFR mutations. 
Preclinical data have indicated that EGFR exon 18 
mutations (exon 18 deletions, E709K, and G719A) and 
others (S768I and L861Q) exhibited higher sensitivity to 
afatinib than to erlotinib or osimertinib [40, 41]. In the 
present study, afatinib had a wider therapeutic window 
for G719S than for L861Q. A combined post-hoc analysis 
of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 found 
that the response rate to afatinib was higher for G719X 
(77.8%) than for L861Q (56.3%) [26]. Furthermore, we 
identified limited efficacy of third-generation EGFR-TKIs 
for these mutations, irrespective of the T790M mutation. 
Interestingly, osimertinib was not effective for the patient 
with NSCLC harboring the G719S+T790M mutations. In 
the AURA trial, 7 patients with G719X-positive tumors 
received at least one dose of osimertinib. The objective 
response rate was 14% and the disease control rate was 
57% [22]. In summary, the efficacy of third-generation 
EGFR-TKIs is likely to be lower in patients with the 
EGFR G719X mutation than in those with EGFR classic 
mutations, both in the presence and absence of the T790M 
mutation. Osimertinib and nazartinib showed similar 
potencies and greater mutation specificity than afatinib in 
cells expressing exon 20 insertion mutations, which are 
associated with resistance to first- and second-generation 
EGFR-TKIs. Dose-adjusted clinical trials will be required 
to examine the efficacy of osimertinib or nazartinib for 
patients with NSCLCs harboring these types of exon 20 
insertion mutations.
Structurally, the EGFR T790M mutation induces 
resistance to first- and second-generation EGFR-TKIs 
by altering the gatekeeper residue in the ATP-site and 
increasing the affinity for ATP [21]. The EGFR C797S 
mutation impairs the covalent binding between the 
cysteine residue at position 797 of EGFR and third-
generation EGFR-TKIs [33]. In general, the data obtained 
in this study was reasonable from the structural view point.
The present study was conducted in vitro. To 
develop improved strategies for using EGFR-TKIs, further 
in vivo and human clinical trials will be required because 
EGFR-TKIs may have different pharmacokinetic and 
pharmacodynamic properties that will influence their in 
vivo concentrations.
In summary, the present study provides fundamental 
osimertinib and nazartinib sensitivity/resistance data in 
cells expressing a range of EGFR mutations, including 
those that occur relatively infrequently. The findings 
highlight the diverse mutation-related sensitivity to EGFR-
TKIs. These data may help in the selection of EGFR-TKIs 
for the treatment of NSCLC patients.
MATERIALS AND METHODS
Cell lines
Four human NSCLC cell lines were used: 
PC-9 [EGFR exon 19 deletion (delE746-A750)]; PC-
9ER [EGFR exon 19 deletion (delE746-A750) + 
T790M]; BID007 [EGFR exon 20 insertion (A763_
Y764insFQEA)]; and H1975 [EGFR L858R + T790M]. 
PC9 and BID007 cells were a kind gift from Dr. Susumu 
Oncotarget105489www.impactjournals.com/oncotarget
Kobayashi (Beth Israel Deaconess Medical Center, 
Boston, MA, USA). H1975 cells were purchased from the 
American Type Culture Collection (Manassas, VA, USA). 
PC-9ER cells became resistant to erlotinib after chronic 
exposure to this molecule and acquisition of the EGFR 
T790M mutation. Cell authentication for H1975 was 
performed in June 2015.
Reagents
Erlotinib and afatinib were purchased from LC 
Laboratories (Woburn, MA, USA). Osimertinib was 
purchased from Selleck Chemicals (Houston, TX, USA). 
Nazartinib (#B5889) was purchased from Apexbio. 
Antibodies recognizing total EGFR (#2232), total AKT 
(#9272), phospho-AKT (S473; D9E; #4060), total p44/42 
MAPK (#9102S), and phospho-p44/42 MAPK (T202/204; 
#9101S) were purchased from Cell Signaling Technology 
(Beverly, MA, USA). The phospho-EGFR (Y1068) 
antibody (44788G) was purchased from Invitrogen/Life 
Technologies (Carlsbad, CA, USA), and the actin antibody 
was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Ba/F3 stable cell lines
Ba/F3 cells stably expressing either wild type or 
mutated EGFR were created as previously described [29]. 
Ba/F3 cells harboring EGFR mutations were cultured in 
RPMI-1640 growth medium, supplemented with 10% fetal 
bovine serum, at 37°C in a humidified 5% CO2 incubator. 
Ba/F3 cells expressing wild type EGFR were cultured in 
RPMI-1640 growth medium, supplemented with 10% fetal 
bovine serum, at 37°C in a humidified 5% CO2 incubator 
with EGF (10 ng/mL). The EGFR mutations examined 
in this study included: delL747_P753insS (exon 19del); 
L858R; delL747_P753insS + T790M (exon 19del + 
T790M); L858R + T790M; A763_Y764insFQEA; Y764_
V765insHH; A767_V769dupASV; D770_N771insNPG; 
G719S; L861Q; G719S + T790M; L861Q + T790M; 
delL747_P753insS + T790M + C797S (exon 19del + 
T790M + C797S); and L858R + T790M + C797S.
Cell proliferation assay
The MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay was performed as previously described 
[29]. PC-9, PC-9ER, H1975, and BID007 cells were 
seeded in 96-well plates. Twenty-four hours after seeding, 
the appropriate medium with or without EGFR-TKI was 
added to each well. Control cells were treated with the 
same concentration of the vehicle, dimethyl sulfoxide 
(DMSO). Seventy-two hours after treatment, absorbance 
was measured. For Ba/F3 cells, the cells were seeded 
with or without EGFR-TKI. Seventy-two hours after 
seeding, absorbance was measured. All experiments were 
performed at least three times.
Immunoblotting analysis
Cells were treated with EGFR-TKI at 
concentrations of 0.01–1 μmol/L for 4 h. Cells were 
lysed in Cell Lysis Buffer (Cell Signaling Technology). 
Equal amounts of protein were loaded per lane on sodium 
dodecyl sulfate-polyacrylamide gels. Separated proteins 
were transferred to polyvinylidene fluoride membranes. 
The membranes were incubated overnight with primary 
antibodies at 4°C and then incubated with secondary 
antibodies for 1 h. For the detection of proteins, the 
membranes were incubated with agitation in LumiGLO 
reagent and peroxide (Cell Signaling Technology), and 
then exposed to X-ray film.
Apoptosis assay
Ba/F3 cells harboring wild type EGFR, exon 19del 
+ T790M, Y764_V765insHH, A767_V769dupASV, 
G719S + T790M, or L861Q + T790M were seeded in 
6-well plates. The cells were treated with EGFR-TKIs (0.1 
μM) for 48 h. Control cells were treated with the same 
concentration of the vehicle, DMSO. We analyzed the 
apoptotic status of cells using the Annexin V Apoptosis 
Detection Kit APC (eBioscience, San Diego, CA, USA), 
according to the manufacturer’s protocol. The proportion 
of apoptotic cells was evaluated by flow cytometric 
analysis, using the Gallios flow cytometer system 
(Beckman Coulter, Brea, CA, USA).
Statistical analysis
Statistical analysis was performed using the 
GraphPad Prism software, version 4.0 (GraphPad 
Software, La Jolla, CA, USA). The IC50 values were 
calculated using GraphPad Prism software.
Human data
This study included NSCLC patient data. The 
study was reviewed and approved by the Institutional 
Review Board of Keio University School of Medicine 
(Tokyo, Japan). Tumor samples were obtained with 
written informed consent. EGFR mutation analyses 
were performed on genomic DNA extracted from tumor 
samples by using the PNA-LNA PCR clamp method.
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